KSCM
OCUL icon

Kamunting Street Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Kamunting Street Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-351
Closed -$351K – 61
2021
Q3 		$351K Buy
+351
New +$3.94K 0.16% 48
2019
Q3 		– Sell
-75,000
Closed -$330K – 54
2019
Q2 		$330K Buy
+75,000
New +$278K 0.32% 41

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Kamunting Street Capital Management's OCUL Position: Q3 2022 in Review

Kamunting Street Capital Management sold out of Ocular Therapeutix (OCUL) in Q3 2022, closing a stake of 275,506 shares — an estimated $1.11M sold.

Kamunting Street Capital Management first reported a position in OCUL in Q3 2020 and held it in 8 quarters. The position peaked at $8.85M in Q2 2021. 130 funds tracked by Wall St. Rank hold OCUL as of Q3 2022.

  • Kamunting Street Capital Management reported no remaining Ocular Therapeutix position as of Q3 2022 after selling out during the quarter.
  • Kamunting Street Capital Management sold 275,506 Ocular Therapeutix shares in Q3 2022, an estimated $1.11M.
  • Kamunting Street Capital Management first reported a position in Ocular Therapeutix in Q3 2020 and held it in 8 quarters.
  • Kamunting Street Capital Management's Ocular Therapeutix position peaked at $8.85M in Q2 2021.
  • 130 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2022.

Based on Kamunting Street Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.